CPA’s report, titled “Generic Drug Shortages and How a Race to the Bottom in Price has Upended 30 years of Hatch-Waxman,” details how a loophole in the Hatch-Waxman Act has led to generic drug shortages in the U.S., offshoring of America’s domestic production of generic pharmaceuticals to China and India, and price gouging by foreign…
An Indian drug market that’s been the subject of FDA warnings since 2017 is the apparent source of tainted medication sold in the U.S. and Canada. This is another example as to why we need to reshore critical supply of essential medication. Where is Congress?
How do we bring back generic drug manufacturing to the United States in order to be less reliant on India, China? A National Academies of Science conference brings in some experts to try and answer that, including the chair of CPA Healthcare Committee.
A Senate hearing today looked back at our early response to the pandemic. A year later, what went right, what went wrong, and how to re-shore pharma now.